CD38 / BCMA / Firefly Luciferase CHO Recombinant Cell Line
Recombinant clonal stable CHO cell line constitutively expressing full length human CD38 protein (also known as ADPRC1, Genbank accession #NM_001775) and human BCMA protein (B-Cell Maturation Antigen or CD269, GenBank accession #NM_001192). This cell line was derived from our CHO-K1 Luciferase cells (BPS Bioscience, #79725), therefore it also constitutively expresses the firefly luciferase reporter. Surface expression of CD38 and BCMA was confirmed by flow cytometry.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
Materials Required for Cell Culture
| Name | Ordering Information |
| Thaw Medium 3 | BPS Bioscience #60186 |
| Growth Medium 3K | BPS Bioscience #78041 |
Materials Required for Cellular Assay
| Name | Ordering Information |
| ONE-Step™ Luciferase Assay System | BPS Bioscience #60690 |
| 96-well tissue culture-treated white clear-bottom assay plate | |
| Luminometer |
1. Useful for validation of anti-CD38 and anti-BCMA bispecific antibody.
2. Useful as CD38- and/or BCMA-expressing target cells in co-culture assay with CD38- and/or BCMA-CAR-T cells, for both CD38/BCMA-specific cell killing assay and cytokine production assay.
3. Useful for screening and validating antibodies against CD38 or BCMA and anti CD38 or anti-BCMA CAR-T for immunotherapy research and drug discovery
The cell line has been screened using the MycoAlert™ Mycoplasma Detection kit (Lonza, #LT07-218) to confirm the absence of Mycoplasma species.
The CD38 protein is a dimeric, non-lineage-restricted, type II transmembrane glycoprotein that synthesizes and hydrolyzes the second messengers cyclic ADP-ribose and NADP. CD38 is highly expressed by lymphoid and myeloid cells, particularly plasma cells. Increased CD38 expression on chronic lymphocytic leukemia (CLL) cells is linked to aggressive disease features and poor clinical outcome. CD38 is used as a prognostic marker for patients with CLL and multiple myeloma (MM), and is an ideal target for immunotherapy in CLL and MM.
B-Cell Maturation Antigen (BCMA), also known as CD269, is a cell surface receptor of the TNF receptor superfamily that recognizes B-Cell Activating Factor (BAFF). BCMA is preferentially expressed on mature B-lymphocytes and Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy, not only because of its restricted expression in nonmalignant tissue, but also due to its almost universal expression on MM cells. Pre-clinical studies using CAR (Chimeric Antigen Receptor) T cells targeting BCMA have demonstrated anti-MM activity, and in 2017, the FDA granted BCMA CAR T-Cell immunotherapy the breakthrough designation in treating Multiple Myeloma.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.